Full-Time

Manager – Regulatory Affairs

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$120k - $158kAnnually

Mid, Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Business Strategy
Requirements
  • Bachelor's Degree in a relevant field and at least 3 years of direct Regulatory experience.
  • Strong working knowledge of US FDA Pharmaceutical regulations and guidance.
  • Proven track record of successful submissions within a regulatory environment.
  • Exceptionally strong team player with excellent interpersonal and communication skills.
  • Detail-oriented with strong organizational skills and high-quality standards.
Responsibilities
  • Manage planning, preparation, coordination, and submission of regulatory documents to global National Health Authorities. Such submissions may include Clinical, Preclinical, or CMC content.
  • Correspond and collaborate with RevMed colleagues and departments to achieve alignment.
  • Function as a Regulatory Affairs subject matter expert member of cross-functional teams, including study teams and submission teams.
  • Perform regulatory research to inform business strategy. Assess and communicate risks.
  • Assure that there are no significant interruptions to the business due to regulatory compliance issues.
  • Collaborates across the organization at all levels, across functional groups, and with executive management.
  • Develop regulatory strategies to inform associated budgets, tools and specialized support necessary for efficient operations.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • Strong investor confidence shown by recent upsized public offering.
  • Growing interest in targeted therapies aligns with their RAS-focused treatments.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M public stock offering could result in shareholder dilution.
  • Focus on RAS-driven cancers limits market scope and growth potential.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?